First Trust Advisors LP Makes New $934,000 Investment in InMode Ltd. (NASDAQ:INMD)

First Trust Advisors LP bought a new position in InMode Ltd. (NASDAQ:INMD - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 55,951 shares of the healthcare company's stock, valued at approximately $934,000. First Trust Advisors LP owned 0.08% of InMode as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of INMD. SBI Securities Co. Ltd. purchased a new stake in InMode in the 4th quarter worth $87,000. Farther Finance Advisors LLC lifted its stake in InMode by 26.2% in the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after purchasing an additional 1,154 shares in the last quarter. Covestor Ltd lifted its stake in InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after purchasing an additional 723 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in InMode in the 4th quarter worth $114,000. Finally, Sterling Capital Management LLC raised its position in shares of InMode by 23.5% during the 4th quarter. Sterling Capital Management LLC now owns 9,162 shares of the healthcare company's stock valued at $153,000 after buying an additional 1,742 shares in the last quarter. Institutional investors own 68.04% of the company's stock.

InMode Stock Up 0.5%

InMode stock traded up $0.08 during midday trading on Tuesday, reaching $15.08. The stock had a trading volume of 502,251 shares, compared to its average volume of 1,268,484. InMode Ltd. has a 52-week low of $13.68 and a 52-week high of $19.85. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 6.42 and a beta of 2.02. The company has a fifty day moving average of $16.35 and a 200 day moving average of $17.42.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a return on equity of 18.25% and a net margin of 45.91%. The firm had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. During the same period last year, the company earned $0.32 earnings per share. The business's revenue for the quarter was down 3.0% compared to the same quarter last year. Equities research analysts predict that InMode Ltd. will post 1.75 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on INMD shares. Jefferies Financial Group decreased their target price on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Baird R W cut shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Monday, April 28th. UBS Group decreased their target price on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Finally, Barclays decreased their target price on shares of InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $18.54.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.